|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MRPL53 |
Gene summary for MRPL53 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MRPL53 | Gene ID | 116540 |
| Gene name | mitochondrial ribosomal protein L53 | |
| Gene Alias | L53MT | |
| Cytomap | 2p13.1 | |
| Gene Type | protein-coding | GO ID | GO:0000313 | UniProtAcc | Q96EL3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 116540 | MRPL53 | LZE5T | Human | Esophagus | ESCC | 1.48e-05 | 3.08e-01 | 0.0514 |
| 116540 | MRPL53 | LZE24T | Human | Esophagus | ESCC | 2.20e-04 | 1.43e-01 | 0.0596 |
| 116540 | MRPL53 | P1T-E | Human | Esophagus | ESCC | 1.64e-05 | 2.78e-01 | 0.0875 |
| 116540 | MRPL53 | P2T-E | Human | Esophagus | ESCC | 3.60e-13 | 2.16e-01 | 0.1177 |
| 116540 | MRPL53 | P4T-E | Human | Esophagus | ESCC | 3.18e-14 | 3.40e-01 | 0.1323 |
| 116540 | MRPL53 | P5T-E | Human | Esophagus | ESCC | 6.56e-15 | 3.11e-01 | 0.1327 |
| 116540 | MRPL53 | P8T-E | Human | Esophagus | ESCC | 4.40e-09 | 1.57e-01 | 0.0889 |
| 116540 | MRPL53 | P9T-E | Human | Esophagus | ESCC | 3.82e-08 | 1.95e-01 | 0.1131 |
| 116540 | MRPL53 | P10T-E | Human | Esophagus | ESCC | 4.31e-06 | 1.59e-01 | 0.116 |
| 116540 | MRPL53 | P11T-E | Human | Esophagus | ESCC | 6.74e-09 | 2.94e-01 | 0.1426 |
| 116540 | MRPL53 | P12T-E | Human | Esophagus | ESCC | 2.05e-07 | 1.96e-01 | 0.1122 |
| 116540 | MRPL53 | P15T-E | Human | Esophagus | ESCC | 1.53e-11 | 2.36e-01 | 0.1149 |
| 116540 | MRPL53 | P16T-E | Human | Esophagus | ESCC | 2.03e-09 | 1.66e-01 | 0.1153 |
| 116540 | MRPL53 | P17T-E | Human | Esophagus | ESCC | 7.64e-08 | 3.15e-01 | 0.1278 |
| 116540 | MRPL53 | P19T-E | Human | Esophagus | ESCC | 5.57e-05 | 3.45e-01 | 0.1662 |
| 116540 | MRPL53 | P20T-E | Human | Esophagus | ESCC | 1.73e-12 | 2.62e-01 | 0.1124 |
| 116540 | MRPL53 | P21T-E | Human | Esophagus | ESCC | 9.53e-09 | 2.31e-01 | 0.1617 |
| 116540 | MRPL53 | P22T-E | Human | Esophagus | ESCC | 7.98e-13 | 2.45e-01 | 0.1236 |
| 116540 | MRPL53 | P23T-E | Human | Esophagus | ESCC | 2.24e-10 | 2.83e-01 | 0.108 |
| 116540 | MRPL53 | P26T-E | Human | Esophagus | ESCC | 1.47e-14 | 3.12e-01 | 0.1276 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MRPL53 | SNV | Missense_Mutation | rs150499635 | c.19C>T | p.Arg7Trp | p.R7W | Q96EL3 | protein_coding | deleterious(0.01) | benign(0.165) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
| MRPL53 | SNV | Missense_Mutation | novel | c.70G>C | p.Glu24Gln | p.E24Q | Q96EL3 | protein_coding | deleterious(0.03) | benign(0.38) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MRPL53 | SNV | Missense_Mutation | rs202083153 | c.217N>T | p.Arg73Cys | p.R73C | Q96EL3 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-D8-A1JC-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
| MRPL53 | SNV | Missense_Mutation | rs773890839 | c.317C>T | p.Pro106Leu | p.P106L | Q96EL3 | protein_coding | deleterious_low_confidence(0.05) | probably_damaging(0.995) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MRPL53 | SNV | Missense_Mutation | c.72N>T | p.Glu24Asp | p.E24D | Q96EL3 | protein_coding | tolerated(0.08) | benign(0.074) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
| MRPL53 | SNV | Missense_Mutation | novel | c.61T>A | p.Cys21Ser | p.C21S | Q96EL3 | protein_coding | tolerated(0.07) | probably_damaging(0.986) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| MRPL53 | SNV | Missense_Mutation | novel | c.146N>T | p.Cys49Phe | p.C49F | Q96EL3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| MRPL53 | SNV | Missense_Mutation | novel | c.60N>A | p.Phe20Leu | p.F20L | Q96EL3 | protein_coding | tolerated(0.06) | possibly_damaging(0.809) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| MRPL53 | SNV | Missense_Mutation | novel | c.124N>A | p.Val42Ile | p.V42I | Q96EL3 | protein_coding | tolerated(0.39) | benign(0.003) | TCGA-BG-A221-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MRPL53 | insertion | Frame_Shift_Ins | novel | c.77_78insG | p.Asn26LysfsTer15 | p.N26Kfs*15 | Q96EL3 | protein_coding | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |